Kymera Therapeutics (NASDAQ: KYMR) reported Q1 EPS of ($0.69), $0.02 better than the analyst estimate of ($0.71). Revenue for the quarter came in at $10.3 million versus the consensus estimate of $13.78 million.

For earnings history and earnings-related data on Kymera Therapeutics (KYMR) click here.